A Study to Assess the Safety, Pharmacokinetics and Anti T... | NCT04393298 | Trialant
NCT04393298
Sponsor
UCB Biopharma SRL
Status
Completed
Last Update Posted
May 29, 2025Actual
Enrollment
93Actual
Phase
Phase 1Phase 2
Conditions
Advanced Solid Tumors
Interventions
ginisortamab
trifluridine/tipiracil
mFOLFOX6
Countries
United States
United Kingdom
Protocol Section
Identification Module
NCT ID
NCT04393298
Obsolete or Duplicate NCT IDs
Not provided
Organization Study
ONC001
Secondary IDs
ID
Type
Description
Link
2019-002598-78
EudraCT Number
Brief Title
A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors
Official Title
A Phase 1/2 Open-Label, Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors
Acronym
Not provided
Organization
UCB PharmaINDUSTRY
Status Module
Record Verification Date
May 2025
Overall Recruitment Status or Expanded Access Status
Completed
Last Known Status
Not provided
Delayed Posting
Not provided
Why Stopped
Not provided
Expanded Access Info
No
Start Date
Jul 9, 2020Actual
Primary Completion Date
Apr 11, 2024Actual
Completion Date
Apr 11, 2024Actual
First Submitted Date
Mar 3, 2020
First Submission Date that Met QC Criteria
May 15, 2020
First Posted Date
May 19, 2020Actual
Results Waived
Not provided
Results First Submitted Date
Apr 11, 2025
Results First Submitted that Met QC Criteria
May 26, 2025
Results First Posted Date
May 29, 2025Actual
Certification/Extension (aka Delayed Results) First Submitted Date
Not provided
Certification/Extension First Submitted that Passed QC Review
Not provided
Certification/Extension First Posted Date
Not provided
Last Update Submitted Date
May 26, 2025
Last Update Posted Date
May 29, 2025Actual
Sponsor/Collaborators Module
Responsible Party, by Official Title
Sponsor
Lead Sponsor
UCB Biopharma SRLINDUSTRY
Collaborators
Not provided
Oversight Module
Has Data Monitoring Committee (DMC)
No
Is FDA Regulated Drug
Yes
Is FDA Regulated Device
No
Is Unapproved Device
Not provided
Pediatric Postmarket Surveillance of a Device Product
Not provided
Product Exported from US
Not provided
FDAAA801 Violation
Not provided
Description Module
Brief Summary
The purpose of the study is to characterize the safety and pharmacokinetic (PK) profile of UCB6114 administered as monotherapy or in combination with selected standard of care (SOC) regimens.
Detailed Description
Not provided
Conditions Module
Conditions
Advanced Solid Tumors
Keywords
Advanced solid tumors
UCB6114
Phase 1/2
Design Module
Study Type
Interventional
Number of References to an Expanded Access Study
Not provided
Expanded Access Types
Not provided
Patient Registry
Not provided
Target Follow-Up Duration
Not provided
Phases
Phase 1Phase 2
Interventional Study Design
Allocation
Biospecimen
No data available
No data is available for this block.
Enrollment
93Actual
Arms/Interventions Module
Arm Groups
Label
Type
Description
Intervention Names
Part A
Experimental
Study participants assigned this arm will receive UCB6114 as monotherapy in escalating cohorts at pre-specified dose levels.
Drug: ginisortamab
Part A1
Experimental
Study participants will receive predefined doses of UCB6114 as monotherapy administered intravenously at pre-specified time points.
Drug: ginisortamab
Part B
Experimental
Study participants assigned to this arm will receive UCB6114 in escalating cohorts at pre-specified dose levels in combination with trifluridine/tipiracil (TFD/TPI).
Drug: ginisortamab
Drug: trifluridine/tipiracil
Part C
Experimental
Study participants assigned to this arm will receive UCB6114 in escalating cohorts at pre-specified dose levels in combination with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) regimen.
Drug: ginisortamab
Drug: mFOLFOX6
Interventions
Name
Type
Description
Arm Group Labels
Other Names
ginisortamab
Drug
Study participants will receive predefined doses of ginisortamab (UCB6114) administered intravenously at pre-specified time points.
Part A
Part A1
Outcomes Module
Primary Outcomes
Measure
Description
Time Frame
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study medication. A treatment-emergent adverse event (TEAE) was defined as any AE with a start date on or after the first dose of UCB6114 up until the last dose of Ginisortamab (UCB6114) +30 days (i.e. up to 3.8 years).
From Baseline until the End of Study (up to 3.8 years)
Percentage of Participants Based on Severity of Treatment-emergent Adverse Events
AE is any untoward medical occurrence in patient or clinical study participant, temporally associated with use of study medication, whether or not considered related to study medication. AE can therefore be any unfavorable and unintended sign (including abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with use of study medication. TEAE: any AE with start date on or after first dose of UCB6114 up until last dose of Ginisortamab(UCB6114)+30 days. Event for which no Common Terminology Criteria for AE (CTCAE) severity grade was recorded by investigator but intensity was recorded instead was assigned as follows to CTCAE severity grade:Severe=Grade 3, Life Threatening (indicated on electronic case report form (eCRF) for event that is serious)=Grade 4, Death (indicated on the eCRF for event that is serious or has outcome of death)=Grade 5. As planned, data reported for National Cancer Institute (NCI) CTCAE grade >=3 TEAEs and related TEAEs.
From Baseline until the End of Study (up to 3.8 years)
Number of Participants With Dose-limiting Toxicities (DLTs)
DLT defined as any AE at least related to study medication that occurs during Cycle 1 and met following criteria: Grade (Gr) 3 or 4 nonhematological toxicity according to NCI CTCAE (Version 5.0) except for alopecia, or nausea, vomiting, or diarrhea that reverses to Gr ≤2 within 24 hours (hr) with appropriate medical therapy; Gr 3 or 4 biochemical abnormality that persists despite maximal supportive treatment or biochemical abnormalities that is symptomatic and nontransient; Any Gr ≥3 hematological toxicity of >5 days duration or febrile neutropenia (absolute neutrophil count [ANC]<1000/cubic millimeter[mm3] with single temperature of >38.3°C or sustained temperature ≥38°C for more than one hr), infection with Gr 3 or 4 neutropenia, thrombocytopenia with bleeding or requiring platelet transfusion, or Gr 4 thrombocytopenia; Prolonged Gr 2 diarrhea (>7 days) despite adequate antidiarrheal medication, or multiple Grade 1or 2 toxicities(eg, Gr 1 or 2 diarrhea, vomiting, rash, and fatigue).
Secondary Outcomes
Measure
Description
Time Frame
Part A and A1: UCB6114 Serum Concentration by Scheduled Assessment and Cohort
Blood samples for ginisortamab serum concentration analysis were collected at different timepoints following the first dose of ginisortamab. The data is reported for Part A and A1. Pharmacokinetic Set (PKS). Lower Limit of Quantitation (LLOQ).
Parts A: Cycle 1 (Day 1 end of infusion [EOI] and Day 15 Predose), Cycle 2 (Day 1 Predose and Day 15 Predose); Part A 1: Cycle 1 (Day 1 EOI and Day 15 Predose), Cycle 2 (Day 1 Predose)
Other Outcomes
Not provided
Eligibility Module
Eligibility Criteria
Inclusion Criteria:
Participant must be at least 18 years of age inclusive, at the time of signing the informed consent
Participant has advanced disease (ie, locally advanced or metastatic)
Participant has measurable or non-measurable disease as defined by the relevant Response Evaluation Criteria in Solid Tumors (RECIST)
Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
Part A specific:
- Participant has a histologically and/or cytologically confirmed diagnosis of one of the following advanced solid tumor types: colorectal adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic adenocarcinoma, prostate adenocarcinoma, stomach adenocarcinoma, bladder urothelial carcinoma, or breast invasive carcinoma
Part B and C specific:
- Participant has a histologically and/or cytologically confirmed diagnosis of one of the following advanced solid tumor types: colorectal adenocarcinoma, gastric adenocarcinoma, or adenocarcinoma of the gastroesophageal junction
Part A1 specific:
- Participant has histologically and/or cytologically confirmed diagnosis of one of the following advanced solid tumor types: colorectal adenocarcinoma, gastric adenocarcinoma, adenocarcinoma of the gastroesophageal junction, or pancreatic cancer
Exclusion Criteria:
Participant has a known hypersensitivity to any components of the study medications or comparable drugs
Active and clinically significant bacterial, fungal, or viral infection, known infections with hepatitis B, hepatitis C, known human immunodeficiency virus, or acquired immunodeficiency syndrome related illness
Symptomatic central nervous system (CNS) malignancy or metastases. Screening of asymptomatic participants without history of CNS metastases is not required. Participants with asymptomatic CNS lesions should have completed standard therapy for their CNS lesions prior to study enrolment
Current hematologic malignancies
Prior organ or allogeneic stem-cell transplantation
QT interval corrected (QTc) >450 msec
Participant has impaired renal function
Alanine transaminase or AST are ≥2xULN (if liver metastases are present: ≥5xULN)
Participant has moderate or severe cardiovascular disease
Current or chronic history of liver disease or known hepatic or biliary abnormalities other than liver metastases
Davies GCG, Dedi N, Jones PS, Kevorkian L, McMillan D, Ottone C, Schulze MED, Scott-Tucker A, Tewari R, West S, Wright M, Rowley TF. Discovery of ginisortamab, a potent and novel anti-gremlin-1 antibody in clinical development for the treatment of cancer. MAbs. 2023 Jan-Dec;15(1):2289681. doi: 10.1080/19420862.2023.2289681. Epub 2023 Dec 12.
See Also Links
Not provided
Available IPD Information
Not provided
IPD Sharing Statement Module
Plan to Share IPD
Yes
Description
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Types
Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame
Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access Criteria
Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
The Participant Flow refers to the Safety Set (SS).
Recruitment Details
The study started to enroll participants in July 2020 and concluded in April 2024.
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
FG000
Part A: Ginisortamab 100 mg
Participants received ginisortamab monotherapy 100 milligrams (mg) as an intravenously (iv) infusion every 2 weeks (Q2W) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
FG001
Periods
Title
Milestones
Reasons Not Completed
Overall Study
Type
Comment
Milestone Data
STARTED
Baseline Characteristics Module
Baseline Analysis Population Description
Outcome Measures Module
Outcome Measures
Adverse Events Module
Frequency Threshold
5
More Info Module
Limitations and Caveats
Not provided
Annotation Section
No data available
No data is available for this block.
Document Section
Large Document Module
Document Has No Statistical Analysis Plan (SAP)
Not provided
Uploaded Document Information
Type
Includes Protocol
Includes SAP
Includes ICF
Document Label
Document Date
Document Uploaded Date
Document File Name
Prot
Yes
No
No
Study Protocol
Jun 26, 2023
Apr 10, 2025
Derived Section
Miscellaneous Info Module
Version Holder
Jul 10, 2026
Removed Countries
Not provided
Submission Tracking
Estimated Results First Submitted Date
Not provided
Condition Browse Module
No data available
No data is available for this block.
Intervention Browse Module
MeSH Terms
Non-Randomized
Intervention Model
Sequential Assignment
Intervention Model Description
Modular design, escalation & expansion modules. Depending on emerging data, not all modules may open
Primary Purpose
Treatment
Observational Model
Not provided
Time Perspective
Not provided
Masking Info
Masking
None (Open Label)
Masking Description
Not provided
Who Masked
Not provided
Part B
Part C
UCB6114
trifluridine/tipiracil
Drug
Study participants will receive predefined doses of trifluridine/tipiracil (TFD/TPI) administered as film-coated tablets at pre-specified time points.
Part B
TAS-102
Lonsurf®
mFOLFOX6
Drug
Study participants will receive predefined doses of oxaliplatin, Leucovorin and 5-fluorouracil as part of the mFOLFOX6 chemotherapy regimen administered as intravenous (iv) infusion at prespecified time points.
Part C
Calcium folinate
5-FU
fluorouracil
From Baseline throughout 28 days (Cycle 1)
Part B and C: UCB6114 Concentration by Scheduled Assessment and Dose Level
Blood samples for ginisortamab serum concentration analysis were collected at timepoints following (Cycle 1 Day 1) and the (Cycle 2 Day 1) administration of ginisortamab. Data is reported for Part B and Part C.
Part B and C: Cycle 1 (Day 1 EOI and Day 15 Predose), Cycle 2 (Day 1 Predose and Day 15 Predose)
Charleston
South Carolina
29425
United States
Onc001 50471
Houston
Texas
77030
United States
Onc001 40305
Glasgow
United Kingdom
Onc001 40113
London
United Kingdom
Onc001 40304
Manchester
United Kingdom
Onc001 40306
Newcastle upon Tyne
United Kingdom
Onc001 40303
Oxford
United Kingdom
Onc001 40302
Sutton
United Kingdom
Part A: Ginisortamab 250 mg
Participants received ginisortamab monotherapy 250 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
FG002
Part A: Ginisortamab 500 mg
Participants received ginisortamab monotherapy 500 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
FG003
Part A: Ginisortamab 1000 mg
Participants received ginisortamab monotherapy 1000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
FG004
Part A: Ginisortamab 2000 mg
Participants received ginisortamab monotherapy 2000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
FG005
Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (60-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
FG006
Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (30-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
FG007
Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D
Participants received ginisortamab monotherapy 3000 mg as an iv infusion (90-minute infusion) every 3 weeks (Q3W) on Day 1 of each 21-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
FG008
Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D
Participants received ginisortamab monotherapy 4000 mg as an iv infusion (120-minute infusion) every 4 weeks (Q4W) on Day 1 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
FG009
Part B: Ginisortamab 500 mg + TFD/TPI SoC
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with orally administered trifluridine/tipiracil (TFD/TPI) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
FG010
Part B: Ginisortamab 1000 mg + TFD/TPI SoC
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
FG011
Part B: Ginisortamab 2000 mg + TFD/TPI SoC
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
FG012
Part C: Ginisortamab 500 mg + mFOLFOX6 SoC
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
FG013
Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
FG014
Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
FG0003 subjects
FG0015 subjects
FG0025 subjects
FG0036 subjects
FG0046 subjects
FG0058 subjects
FG0068 subjects
FG0078 subjects
FG0088 subjects
FG0099 subjects
FG0104 subjects
FG0118 subjects
FG0125 subjects
FG0133 subjects
FG0147 subjects
COMPLETED
FG0001 subjects
FG0011 subjects
FG0022 subjects
FG0033 subjects
FG0043 subjects
FG0051 subjects
FG0064 subjects
FG0075 subjects
FG0082 subjects
FG0095 subjects
FG0103 subjects
FG0113 subjects
FG0123 subjects
FG0132 subjects
FG0140 subjects
NOT COMPLETED
FG0002 subjects
FG0014 subjects
FG0023 subjects
FG0033 subjects
FG0043 subjects
FG0057 subjects
FG0064 subjects
FG0073 subjects
FG0086 subjects
FG0094 subjects
FG0101 subjects
FG0115 subjects
FG0122 subjects
FG0131 subjects
FG0147 subjects
Type
Comment
Reasons
Adverse Event
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG0041 subjects
FG0050 subjects
FG0060 subjects
FG0070 subjects
FG0082 subjects
FG0090 subjects
FG0100 subjects
FG0110 subjects
FG0121 subjects
FG0131 subjects
FG0140 subjects
Consent withdrawn by participant, not due to AE
FG0000 subjects
FG0010 subjects
FG0021 subjects
FG0030 subjects
Lack of Efficacy
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Progression
FG0001 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Passed Away on The 30 Oct 2020
FG0001 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Disease Progression Confirmed by Scans (CT/MRI)
FG0000 subjects
FG0011 subjects
FG0020 subjects
FG0030 subjects
Clinical Progression
FG0000 subjects
FG0012 subjects
FG0020 subjects
FG0030 subjects
FG004
Disease Progression
FG0000 subjects
FG0011 subjects
FG0020 subjects
FG0030 subjects
FG004
Since no Treatment Administered at Cycle 2 Day 15
FG0000 subjects
FG0010 subjects
FG0021 subjects
FG0030 subjects
Further Deterioration Noted at Clinic review
FG0000 subjects
FG0010 subjects
FG0021 subjects
FG0030 subjects
Progressive Disease (PD)
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0033 subjects
FG004
Started a New Cancer Treatment
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Sponsor decision- sepsis (treatment delay)
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
Due to symptoms (New Brain Metastases)
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Clinical Progression: Not suitable for SFU return
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
Death
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Progressive Disease - New Brain Mets on CT Head
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
Progressive Disease and Subsequent Death
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Patient Passed Away
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Patient Deceased
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Patient Discharged to Hospice
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Symptomatic Cancer - Unfit to take a call
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Clinical Progression in Combination with AE
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
Baseline Characteristics refer to the Safety Set (SS) which consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
BG000
Part A: Ginisortamab 100 mg
Participants received ginisortamab monotherapy 100 milligrams (mg) as an intravenously (iv) infusion every 2 weeks (Q2W) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
BG001
Part A: Ginisortamab 250 mg
Participants received ginisortamab monotherapy 250 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
BG002
Part A: Ginisortamab 500 mg
Participants received ginisortamab monotherapy 500 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
BG003
Part A: Ginisortamab 1000 mg
Participants received ginisortamab monotherapy 1000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
BG004
Part A: Ginisortamab 2000 mg
Participants received ginisortamab monotherapy 2000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
BG005
Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (60-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
BG006
Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (30-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
BG007
Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D
Participants received ginisortamab monotherapy 3000 mg as an iv infusion (90-minute infusion) every 3 weeks (Q3W) on Day 1 of each 21-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
BG008
Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D
Participants received ginisortamab monotherapy 4000 mg as an iv infusion (120-minute infusion) every 4 weeks (Q4W) on Day 1 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
BG009
Part B: Ginisortamab 500 mg + TFD/TPI SoC
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with orally administered trifluridine/tipiracil (TFD/TPI) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
BG010
Part B: Ginisortamab 1000 mg + TFD/TPI SoC
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
BG011
Part B: Ginisortamab 2000 mg + TFD/TPI SoC
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
BG012
Part C: Ginisortamab 500 mg + mFOLFOX6 SoC
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
BG013
Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
BG014
Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
BG015
Total
Total of all reporting groups
Denominators
Units
Counts
Participants
BG0003
BG0015
BG0025
BG0036
BG0046
BG0058
BG0068
BG0078
BG0088
BG0099
BG0104
BG0118
BG0125
BG0133
BG0147
BG01593
Baseline Measures
Title
Description
Population Description
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Denominator Units Selected
Denominators
Classes
Age, Continuous
Mean
Standard Deviation
Years
Title
Denominators
Categories
Title
Measurements
BG00065.0± 1.0
BG00154.4± 11.0
BG00258.2± 12.2
BG003
Age, Customized
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
18 - <65 years
BG0001
BG0014
BG002
Sex: Female, Male
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Female
BG0000
BG0012
BG002
Race/Ethnicity, Customized
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Asian
BG0000
BG0011
BG002
Race/Ethnicity, Customized
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Not Hispanic or Latino
BG0003
BG0015
BG002
Type
Title
Description
Population Description
Reporting Status
Anticipated Posting Date
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Time Frame
Units Analyzed
Denominator Units Selected
Arm/Group Information
Denominators
Classes
Analyses
Primary
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study medication. A treatment-emergent adverse event (TEAE) was defined as any AE with a start date on or after the first dose of UCB6114 up until the last dose of Ginisortamab (UCB6114) +30 days (i.e. up to 3.8 years).
The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
Posted
Number
percentage of participants
From Baseline until the End of Study (up to 3.8 years)
ID
Title
Description
OG000
Part A: Ginisortamab 100 mg
Participants received ginisortamab monotherapy 100 milligrams (mg) as an intravenously (iv) infusion every 2 weeks (Q2W) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG001
Part A: Ginisortamab 250 mg
Participants received ginisortamab monotherapy 250 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG002
Part A: Ginisortamab 500 mg
Participants received ginisortamab monotherapy 500 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG003
Part A: Ginisortamab 1000 mg
Participants received ginisortamab monotherapy 1000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG004
Part A: Ginisortamab 2000 mg
Participants received ginisortamab monotherapy 2000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG005
Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (60-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG006
Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (30-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG007
Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D
Participants received ginisortamab monotherapy 3000 mg as an iv infusion (90-minute infusion) every 3 weeks (Q3W) on Day 1 of each 21-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG008
Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D
Participants received ginisortamab monotherapy 4000 mg as an iv infusion (120-minute infusion) every 4 weeks (Q4W) on Day 1 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG009
Part B: Ginisortamab 500 mg + TFD/TPI SoC
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with orally administered trifluridine/tipiracil (TFD/TPI) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG010
Part B: Ginisortamab 1000 mg + TFD/TPI SoC
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG011
Part B: Ginisortamab 2000 mg + TFD/TPI SoC
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG012
Part C: Ginisortamab 500 mg + mFOLFOX6 SoC
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG013
Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG014
Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
Units
Counts
Participants
OG0003
OG0015
OG0025
OG003
Title
Denominators
Categories
Title
Measurements
OG000100
OG001100
OG002100
OG003
Primary
Percentage of Participants Based on Severity of Treatment-emergent Adverse Events
AE is any untoward medical occurrence in patient or clinical study participant, temporally associated with use of study medication, whether or not considered related to study medication. AE can therefore be any unfavorable and unintended sign (including abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with use of study medication. TEAE: any AE with start date on or after first dose of UCB6114 up until last dose of Ginisortamab(UCB6114)+30 days. Event for which no Common Terminology Criteria for AE (CTCAE) severity grade was recorded by investigator but intensity was recorded instead was assigned as follows to CTCAE severity grade:Severe=Grade 3, Life Threatening (indicated on electronic case report form (eCRF) for event that is serious)=Grade 4, Death (indicated on the eCRF for event that is serious or has outcome of death)=Grade 5. As planned, data reported for National Cancer Institute (NCI) CTCAE grade >=3 TEAEs and related TEAEs.
The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
Posted
Number
percentage of participants
From Baseline until the End of Study (up to 3.8 years)
ID
Title
Description
OG000
Part A: Ginisortamab 100 mg
Participants received ginisortamab monotherapy 100 milligrams (mg) as an intravenously (iv) infusion every 2 weeks (Q2W) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG001
Primary
Number of Participants With Dose-limiting Toxicities (DLTs)
DLT defined as any AE at least related to study medication that occurs during Cycle 1 and met following criteria: Grade (Gr) 3 or 4 nonhematological toxicity according to NCI CTCAE (Version 5.0) except for alopecia, or nausea, vomiting, or diarrhea that reverses to Gr ≤2 within 24 hours (hr) with appropriate medical therapy; Gr 3 or 4 biochemical abnormality that persists despite maximal supportive treatment or biochemical abnormalities that is symptomatic and nontransient; Any Gr ≥3 hematological toxicity of >5 days duration or febrile neutropenia (absolute neutrophil count [ANC]<1000/cubic millimeter[mm3] with single temperature of >38.3°C or sustained temperature ≥38°C for more than one hr), infection with Gr 3 or 4 neutropenia, thrombocytopenia with bleeding or requiring platelet transfusion, or Gr 4 thrombocytopenia; Prolonged Gr 2 diarrhea (>7 days) despite adequate antidiarrheal medication, or multiple Grade 1or 2 toxicities(eg, Gr 1 or 2 diarrhea, vomiting, rash, and fatigue).
The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
Posted
Count of Participants
Participants
From Baseline throughout 28 days (Cycle 1)
ID
Title
Description
OG000
Part A: Ginisortamab 100 mg
Participants received ginisortamab monotherapy 100 milligrams (mg) as an intravenously (iv) infusion every 2 weeks (Q2W) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG001
Secondary
Part A and A1: UCB6114 Serum Concentration by Scheduled Assessment and Cohort
Blood samples for ginisortamab serum concentration analysis were collected at different timepoints following the first dose of ginisortamab. The data is reported for Part A and A1. Pharmacokinetic Set (PKS). Lower Limit of Quantitation (LLOQ).
PKS:all participants of SS with >=1 evaluable PKS concentration (ie, sample above LLOQ[0.02μg/mL] and for which date, sample time, prior date dosing time are known). Number analyzed:participants evaluable at specified time points. Dosing was only performed on Day 1 of each cycle for Part A1:Ginisortamab 3000mg Q3W(90-min) 21-day and Ginisortamab 4000mg Q4W(120-min) 28-day arms. Hence, Predose, Day 15 of Cycle 1 was not collected. No arms of Part A1 had data collection on Cycle 2 Day 15 Predose.
Posted
Geometric Mean
Geometric Coefficient of Variation
microgram per milliliter (ug/mL)
Parts A: Cycle 1 (Day 1 end of infusion [EOI] and Day 15 Predose), Cycle 2 (Day 1 Predose and Day 15 Predose); Part A 1: Cycle 1 (Day 1 EOI and Day 15 Predose), Cycle 2 (Day 1 Predose)
ID
Title
Description
OG000
Part A: Ginisortamab 100 mg
Participants received ginisortamab monotherapy 100 milligrams (mg) as an intravenously (iv) infusion every 2 weeks (Q2W) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG001
Part A: Ginisortamab 250 mg
Secondary
Part B and C: UCB6114 Concentration by Scheduled Assessment and Dose Level
Blood samples for ginisortamab serum concentration analysis were collected at timepoints following (Cycle 1 Day 1) and the (Cycle 2 Day 1) administration of ginisortamab. Data is reported for Part B and Part C.
The PKS included all study participants in the SS (all study participants who received at least 1 full or partial dose of Ginisortamab [UCB6114]) who had at least 1 evaluable PKS concentration (ie, a sample which is above the lower limit of quantitation [0.02μg/mL] and for which the date and time of the sample and prior date and time of dosing are known). Here, number analyzed signifies participants who were evaluable at specified time points.
Posted
Geometric Mean
Geometric Coefficient of Variation
ug/mL
Part B and C: Cycle 1 (Day 1 EOI and Day 15 Predose), Cycle 2 (Day 1 Predose and Day 15 Predose)
ID
Title
Description
OG000
Part B: Ginisortamab 500 mg + TFD/TPI SoC
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with orally administered trifluridine/tipiracil (TFD/TPI) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG001
Part B: Ginisortamab 1000 mg + TFD/TPI SoC
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
Time Frame
From Baseline up to End of the Study (up to 3.8 years)
Description
A TEAE was defined as any AE with a start date on or after the first dose of UCB6114 until the last dose of Ginisortamab (UCB6114) +30 days. A pre-treatment AE which increased in severity on or after the first dose of study treatment was also counted as a TEAE. The SS consisted of all study participants who received at least 1 full or partial dose of Ginisortamab (UCB6114).
All-Cause Mortality Comment
Not provided
Arm/Groups
ID
Title
Description
Deaths (Affected)
Deaths (At Risk)
Serious Events (Affected)
Serious Events (At Risk)
Other Events (Affected)
Other Events (At Risk)
EG000
Part A: Ginisortamab 100 mg
Participants received ginisortamab monotherapy 100 milligrams (mg) as an intravenously (iv) infusion every 2 weeks (Q2W) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
1
3
2
3
3
3
EG001
Part A: Ginisortamab 250 mg
Participants received ginisortamab monotherapy 250 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
0
5
3
5
5
5
EG002
Part A: Ginisortamab 500 mg
Participants received ginisortamab monotherapy 500 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
0
5
1
5
5
5
EG003
Part A: Ginisortamab 1000 mg
Participants received ginisortamab monotherapy 1000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
0
6
0
6
6
6
EG004
Part A: Ginisortamab 2000 mg
Participants received ginisortamab monotherapy 2000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
0
6
1
6
6
6
EG005
Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (60-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
0
8
1
8
7
8
EG006
Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (30-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
0
8
2
8
8
8
EG007
Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D
Participants received ginisortamab monotherapy 3000 mg as an iv infusion (90-minute infusion) every 3 weeks (Q3W) on Day 1 of each 21-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
0
8
2
8
7
8
EG008
Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D
Participants received ginisortamab monotherapy 4000 mg as an iv infusion (120-minute infusion) every 4 weeks (Q4W) on Day 1 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
1
8
5
8
8
8
EG009
Part B: Ginisortamab 500 mg + TFD/TPI SoC
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with orally administered trifluridine/tipiracil (TFD/TPI) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
0
9
4
9
9
9
EG010
Part B: Ginisortamab 1000 mg + TFD/TPI SoC
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
0
4
2
4
4
4
EG011
Part B: Ginisortamab 2000 mg + TFD/TPI SoC
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
0
8
4
8
8
8
EG012
Part C: Ginisortamab 500 mg + mFOLFOX6 SoC
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
0
5
5
5
5
5
EG013
Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
1
3
1
3
3
3
EG014
Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
1
7
2
7
7
7
Serious Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Abdominal pain upper
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected5 at risk
EG0030 events0 affected6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
Nausea
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Lower respiratory tract infection bacterial
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Peritonitis bacterial
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Liver abscess
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Pneumonia
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Sepsis
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Urinary tract infection
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected5 at risk
EG003
Overdose
Injury, poisoning and procedural complications
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Toxicity to various agents
Injury, poisoning and procedural complications
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Musculoskeletal pain
Musculoskeletal and connective tissue disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected5 at risk
EG003
Sacral pain
Musculoskeletal and connective tissue disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected5 at risk
EG003
Urogenital fistula
Renal and urinary disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected5 at risk
EG003
Dyspnoea
Respiratory, thoracic and mediastinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Pulmonary embolism
Respiratory, thoracic and mediastinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Myocardial infarction
Cardiac disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Abdominal pain
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Large intestine perforation
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Large intestinal obstruction
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Ascites
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Biliary obstruction
Hepatobiliary disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Urosepsis
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Vascular device infection
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Cancer pain
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Confusional state
Psychiatric disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Hypoxia
Respiratory, thoracic and mediastinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Pleural effusion
Respiratory, thoracic and mediastinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Pulmonary hypertension
Respiratory, thoracic and mediastinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Pulmonary oedema
Respiratory, thoracic and mediastinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Embolism
Vascular disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Anaemia
Blood and lymphatic system disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Febrile neutropenia
Blood and lymphatic system disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Neutropenia
Blood and lymphatic system disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Abdominal pain lower
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Intestinal obstruction
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Vomiting
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Pyrexia
General disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Abdominal infection
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Lower respiratory tract infection
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Neutropenic sepsis
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Staphylococcal bacteraemia
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Back pain
Musculoskeletal and connective tissue disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Tachycardia
Cardiac disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Diarrhoea
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Mallory-Weiss syndrome
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Dysphagia
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Catheter site thrombosis
General disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Humerus fracture
Injury, poisoning and procedural complications
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Infusion related reaction
Injury, poisoning and procedural complications
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Cerebrovascular accident
Nervous system disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Acute kidney injury
Renal and urinary disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Other Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Anaemia
Blood and lymphatic system disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected5 at risk
EG0031 events1 affected6 at risk
EG0042 events1 affected6 at risk
EG0051 events1 affected8 at risk
EG0061 events1 affected8 at risk
EG0072 events1 affected8 at risk
EG0085 events2 affected8 at risk
EG00912 events5 affected9 at risk
EG0102 events1 affected4 at risk
EG01114 events6 affected8 at risk
EG01211 events3 affected5 at risk
EG0135 events1 affected3 at risk
EG0144 events2 affected7 at risk
Iron deficiency anaemia
Blood and lymphatic system disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Leukocytosis
Blood and lymphatic system disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Lymphopenia
Blood and lymphatic system disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Neutropenia
Blood and lymphatic system disorders
MedDRA 26.1
Non-systematic Assessment
EG0002 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Thrombocytopenia
Blood and lymphatic system disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Arrhythmia supraventricular
Cardiac disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected5 at risk
EG003
Palpitations
Cardiac disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected5 at risk
EG003
Dry eye
Eye disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Eye pain
Eye disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Abdominal discomfort
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Abdominal distension
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Abdominal pain
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Abdominal pain upper
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Abnormal faeces
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Aorto-oesophageal fistula
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Ascites
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Constipation
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected5 at risk
EG003
Diarrhoea
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Dry mouth
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Dyspepsia
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Dysphagia
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Epigastric discomfort
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Eructation
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Food poisoning
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Gastritis
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Gastrooesophageal reflux disease
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0002 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected5 at risk
EG003
Melaena
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Mouth ulceration
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Nausea
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0002 events1 affected3 at risk
EG0012 events2 affected5 at risk
EG0022 events2 affected5 at risk
EG003
Obstruction gastric
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Oesophageal haemorrhage
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Oesophageal stenosis
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Rectal haemorrhage
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Stomatitis
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Toothache
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Vomiting
Gastrointestinal disorders
MedDRA 26.1
Non-systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected5 at risk
EG003
Chest pain
General disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Chills
General disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Fatigue
General disorders
MedDRA 26.1
Non-systematic Assessment
EG0002 events1 affected3 at risk
EG0011 events1 affected5 at risk
EG0023 events3 affected5 at risk
EG003
Feeling cold
General disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Influenza like illness
General disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Mucosal inflammation
General disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Oedema peripheral
General disorders
MedDRA 26.1
Non-systematic Assessment
EG0002 events2 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Peripheral swelling
General disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected5 at risk
EG003
Pyrexia
General disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Hepatomegaly
Hepatobiliary disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected5 at risk
EG003
Hypertransaminasaemia
Hepatobiliary disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Portal vein thrombosis
Hepatobiliary disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Drug hypersensitivity
Immune system disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Abdominal infection
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
COVID-19
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Candida infection
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Cellulitis
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Infection
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Lower respiratory tract infection
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Oral candidiasis
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Pneumonia
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Sinusitis
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Sinusitis bacterial
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Upper respiratory tract infection
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Urinary tract infection
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0022 events1 affected5 at risk
EG003
Urosepsis
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Vaginal infection
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Vascular device infection
Infections and infestations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Contusion
Injury, poisoning and procedural complications
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Craniofacial fracture
Injury, poisoning and procedural complications
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Fall
Injury, poisoning and procedural complications
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Humerus fracture
Injury, poisoning and procedural complications
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Infusion related reaction
Injury, poisoning and procedural complications
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Alanine aminotransferase increased
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Amylase increased
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Aspartate aminotransferase
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Aspartate aminotransferase increased
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0022 events1 affected5 at risk
EG003
Blood alkaline phosphatase increased
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Blood bilirubin increased
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Blood creatine phosphokinase increased
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0022 events1 affected5 at risk
EG003
Blood creatinine increased
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected5 at risk
EG003
Blood lactate dehydrogenase increased
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Blood phosphorus decreased
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Blood triglycerides increased
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
C-reactive protein increased
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Ejection fraction decreased
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Electrocardiogram QT prolonged
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Electrocardiogram T wave amplitude decreased
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Gamma-glutamyltransferase
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Gamma-glutamyltransferase increased
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected5 at risk
EG003
International normalised ratio increased
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Lipase increased
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Lymphocyte count decreased
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Neutrophil count decreased
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Platelet count decreased
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Prothrombin time prolonged
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Weight decreased
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected5 at risk
EG003
White blood cell count decreased
Investigations
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Decreased appetite
Metabolism and nutrition disorders
MedDRA 26.1
Non-systematic Assessment
EG0001 events1 affected3 at risk
EG0011 events1 affected5 at risk
EG0021 events1 affected5 at risk
EG003
Dehydration
Metabolism and nutrition disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Hypercalcaemia
Metabolism and nutrition disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Hyperglycaemia
Metabolism and nutrition disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Hyperlipidaemia
Metabolism and nutrition disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Hypertriglyceridaemia
Metabolism and nutrition disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Hyperuricaemia
Metabolism and nutrition disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Hypocalcaemia
Metabolism and nutrition disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Hypoglycaemia
Metabolism and nutrition disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Hypokalaemia
Metabolism and nutrition disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Hypomagnesaemia
Metabolism and nutrition disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Hyponatraemia
Metabolism and nutrition disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Hypophagia
Metabolism and nutrition disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Hypophosphataemia
Metabolism and nutrition disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Iron deficiency
Metabolism and nutrition disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Vitamin D deficiency
Metabolism and nutrition disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Arthralgia
Musculoskeletal and connective tissue disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Back pain
Musculoskeletal and connective tissue disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected5 at risk
EG003
Bone pain
Musculoskeletal and connective tissue disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0011 events1 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Flank pain
Musculoskeletal and connective tissue disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Limb discomfort
Musculoskeletal and connective tissue disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0021 events1 affected5 at risk
EG003
Muscle spasms
Musculoskeletal and connective tissue disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Musculoskeletal chest pain
Musculoskeletal and connective tissue disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Musculoskeletal pain
Musculoskeletal and connective tissue disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Myalgia
Musculoskeletal and connective tissue disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Neck pain
Musculoskeletal and connective tissue disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Osteoporosis
Musculoskeletal and connective tissue disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Pain in extremity
Musculoskeletal and connective tissue disorders
MedDRA 26.1
Non-systematic Assessment
EG0001 events1 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Pathological fracture
Musculoskeletal and connective tissue disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Synovial cyst
Musculoskeletal and connective tissue disorders
MedDRA 26.1
Non-systematic Assessment
EG0000 events0 affected3 at risk
EG0010 events0 affected5 at risk
EG0020 events0 affected5 at risk
EG003
Cancer pain
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Participants received ginisortamab monotherapy 250 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG002
Part A: Ginisortamab 500 mg
Participants received ginisortamab monotherapy 500 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG003
Part A: Ginisortamab 1000 mg
Participants received ginisortamab monotherapy 1000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG004
Part A: Ginisortamab 2000 mg
Participants received ginisortamab monotherapy 2000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG005
Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (60-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG006
Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (30-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG007
Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D
Participants received ginisortamab monotherapy 3000 mg as an iv infusion (90-minute infusion) every 3 weeks (Q3W) on Day 1 of each 21-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG008
Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D
Participants received ginisortamab monotherapy 4000 mg as an iv infusion (120-minute infusion) every 4 weeks (Q4W) on Day 1 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG009
Part B: Ginisortamab 500 mg + TFD/TPI SoC
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with orally administered trifluridine/tipiracil (TFD/TPI) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG010
Part B: Ginisortamab 1000 mg + TFD/TPI SoC
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG011
Part B: Ginisortamab 2000 mg + TFD/TPI SoC
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG012
Part C: Ginisortamab 500 mg + mFOLFOX6 SoC
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG013
Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG014
Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
Units
Counts
Participants
OG0003
OG0015
OG0025
OG0036
OG0046
OG0058
OG0068
OG0078
OG0088
OG0099
OG0104
OG0118
OG0125
OG0133
OG0147
Title
Denominators
Categories
NCI CTCAE grade >=3 TEAEs
Title
Measurements
OG00066.7
OG00140.0
OG00240.0
OG0030
OG00450.0
OG00562.5
OG00650.0
OG00737.5
OG00862.5
OG00955.6
OG01075.0
OG01187.5
OG012100
OG013100
OG01485.7
NCI CTCAE grade >=3 related TEAEs
Title
Measurements
OG0000
OG0010
OG0020
OG003
Part A: Ginisortamab 250 mg
Participants received ginisortamab monotherapy 250 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG002
Part A: Ginisortamab 500 mg
Participants received ginisortamab monotherapy 500 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG003
Part A: Ginisortamab 1000 mg
Participants received ginisortamab monotherapy 1000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG004
Part A: Ginisortamab 2000 mg
Participants received ginisortamab monotherapy 2000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG005
Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (60-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG006
Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (30-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG007
Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D
Participants received ginisortamab monotherapy 3000 mg as an iv infusion (90-minute infusion) every 3 weeks (Q3W) on Day 1 of each 21-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG008
Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D
Participants received ginisortamab monotherapy 4000 mg as an iv infusion (120-minute infusion) every 4 weeks (Q4W) on Day 1 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG009
Part B: Ginisortamab 500 mg + TFD/TPI SoC
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with orally administered trifluridine/tipiracil (TFD/TPI) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG010
Part B: Ginisortamab 1000 mg + TFD/TPI SoC
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG011
Part B: Ginisortamab 2000 mg + TFD/TPI SoC
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG012
Part C: Ginisortamab 500 mg + mFOLFOX6 SoC
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG013
Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG014
Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
Units
Counts
Participants
OG0003
OG0015
OG0025
OG0036
OG0046
OG0058
OG0068
OG0078
OG0088
OG0099
OG0104
OG0118
OG0125
OG0133
OG0147
Title
Denominators
Categories
Title
Measurements
OG0000
OG0010
OG0020
OG0030
OG0040
OG0050
OG0060
OG0070
OG0080
OG0091
OG0100
OG0111
OG0120
OG0130
OG0140
Participants received ginisortamab monotherapy 250 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG002
Part A: Ginisortamab 500 mg
Participants received ginisortamab monotherapy 500 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG003
Part A: Ginisortamab 1000 mg
Participants received ginisortamab monotherapy 1000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG004
Part A: Ginisortamab 2000 mg
Participants received ginisortamab monotherapy 2000 mg as an iv infusion Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG005
Part A1: Ginisortamab 2000 mg Q2W (60-min), 28D
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (60-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG006
Part A1: Ginisortamab 2000 mg Q2W (30-min), 28D
Participants received ginisortamab monotherapy 2000 mg as an iv infusion (30-minute infusion) Q2W on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG007
Part A1: Ginisortamab 3000 mg Q3W (90-min), 21D
Participants received ginisortamab monotherapy 3000 mg as an iv infusion (90-minute infusion) every 3 weeks (Q3W) on Day 1 of each 21-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG008
Part A1: Ginisortamab 4000 mg Q4W (120-min), 28D
Participants received ginisortamab monotherapy 4000 mg as an iv infusion (120-minute infusion) every 4 weeks (Q4W) on Day 1 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
Units
Counts
Participants
OG0003
OG0015
OG0025
OG0036
OG0046
OG0058
OG0068
OG0078
OG0088
Title
Denominators
Categories
Cycle 1 Day 1 EOI
ParticipantsOG0003
ParticipantsOG0015
ParticipantsOG0024
ParticipantsOG0035
ParticipantsOG0046
ParticipantsOG0058
ParticipantsOG0068
ParticipantsOG0078
ParticipantsOG0085
Title
Measurements
OG00018.0477± 10.0206
OG00172.5261± 24.1924
OG002130.7757± 14.1088
OG003
Cycle 1 Day 15 Predose
ParticipantsOG0003
ParticipantsOG0015
ParticipantsOG0025
ParticipantsOG0036
Cycle 2 Day 1 Predose
ParticipantsOG0002
ParticipantsOG0011
ParticipantsOG0025
ParticipantsOG0036
Cycle 2 Day 15 Predose
ParticipantsOG0001
ParticipantsOG0011
ParticipantsOG0024
ParticipantsOG0035
OG002
Part B: Ginisortamab 2000 mg + TFD/TPI SoC
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with orally administered TFD/TPI on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG003
Part C: Ginisortamab 500 mg + mFOLFOX6 SoC
Participants received ginisortamab 500 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG004
Part C: Ginisortamab 1000 mg + mFOLFOX6 SoC
Participants received ginisortamab 1000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
OG005
Part C: Ginisortamab 2000 mg + mFOLFOX6 SoC
Participants received ginisortamab 2000 mg as an iv infusion Q2W in combination with mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, and 5-fluorouracil) on Day 1 and Day 15 of each 28-day treatment cycle until the occurrence of progressive disease, unacceptable toxicity, or participant withdrawal.
Units
Counts
Participants
OG0009
OG0014
OG0028
OG0035
OG0043
OG0057
Title
Denominators
Categories
Cycle 1 Day 1 EOI
ParticipantsOG0007
ParticipantsOG0014
ParticipantsOG0027
ParticipantsOG0035
ParticipantsOG0043
ParticipantsOG0057
Title
Measurements
OG000104.0606± 15.3565
OG001250.8708± 7.6032
OG002463.5265± 28.6333
OG003
Cycle 1 Day 15 Predose
ParticipantsOG0008
ParticipantsOG0013
ParticipantsOG0027
ParticipantsOG0035
Cycle 2 Day 1 Predose
ParticipantsOG0006
ParticipantsOG0013
ParticipantsOG0026
ParticipantsOG0035
Cycle 2 Day 15 Predose
ParticipantsOG0006
ParticipantsOG0014
ParticipantsOG0025
ParticipantsOG0033
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0041 events1 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0131 events1 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0041 events1 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0141 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0041 events1 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0122 events2 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0132 events1 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0101 events1 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0122 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0051 events1 affected8 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0112 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0112 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0092 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0101 events1 affected4 at risk
EG0112 events1 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0112 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0093 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0113 events1 affected8 at risk
EG0122 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0142 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0122 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0122 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0123 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0132 events1 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0103 events1 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG00914 events5 affected9 at risk
EG01017 events3 affected4 at risk
EG0118 events3 affected8 at risk
EG0121 events1 affected5 at risk
EG0133 events1 affected3 at risk
EG0143 events2 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0093 events2 affected9 at risk
EG0101 events1 affected4 at risk
EG0112 events2 affected8 at risk
EG0123 events1 affected5 at risk
EG0131 events1 affected3 at risk
EG0142 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
1 events
1 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0141 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0141 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0101 events1 affected4 at risk
EG0110 events0 affected8 at risk
EG0122 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0044 events1 affected6 at risk
EG0051 events1 affected8 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected8 at risk
EG0083 events2 affected8 at risk
EG0092 events2 affected9 at risk
EG0104 events2 affected4 at risk
EG0111 events1 affected8 at risk
EG0122 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0143 events3 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0051 events1 affected8 at risk
EG0060 events0 affected8 at risk
EG0072 events2 affected8 at risk
EG0081 events1 affected8 at risk
EG0092 events2 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0141 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
1 events
1 affected
6 at risk
EG0042 events2 affected6 at risk
EG0051 events1 affected8 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected8 at risk
EG0080 events0 affected8 at risk
EG0093 events2 affected9 at risk
EG0101 events1 affected4 at risk
EG0114 events4 affected8 at risk
EG0123 events3 affected5 at risk
EG0132 events2 affected3 at risk
EG0142 events2 affected7 at risk
0 events
0 affected
6 at risk
EG0047 events4 affected6 at risk
EG0050 events0 affected8 at risk
EG0064 events2 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0096 events3 affected9 at risk
EG0102 events2 affected4 at risk
EG0112 events2 affected8 at risk
EG0124 events3 affected5 at risk
EG0133 events2 affected3 at risk
EG0142 events2 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0141 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0041 events1 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0125 events2 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0051 events1 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
1 events
1 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0122 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
3 events
1 affected
6 at risk
EG0044 events4 affected6 at risk
EG0051 events1 affected8 at risk
EG0063 events2 affected8 at risk
EG0073 events2 affected8 at risk
EG0082 events1 affected8 at risk
EG00912 events6 affected9 at risk
EG0103 events2 affected4 at risk
EG0116 events4 affected8 at risk
EG0125 events5 affected5 at risk
EG0130 events0 affected3 at risk
EG0144 events4 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0132 events2 affected3 at risk
EG0141 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0131 events1 affected3 at risk
EG0140 events0 affected7 at risk
1 events
1 affected
6 at risk
EG0042 events2 affected6 at risk
EG0050 events0 affected8 at risk
EG0063 events2 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0096 events5 affected9 at risk
EG0102 events2 affected4 at risk
EG0111 events1 affected8 at risk
EG0127 events4 affected5 at risk
EG0130 events0 affected3 at risk
EG0141 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0042 events1 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0101 events1 affected4 at risk
EG0111 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0141 events1 affected7 at risk
8 events
3 affected
6 at risk
EG0044 events2 affected6 at risk
EG0054 events3 affected8 at risk
EG0066 events5 affected8 at risk
EG0070 events0 affected8 at risk
EG0084 events3 affected8 at risk
EG0098 events5 affected9 at risk
EG0102 events2 affected4 at risk
EG0113 events2 affected8 at risk
EG0123 events2 affected5 at risk
EG0132 events1 affected3 at risk
EG0146 events5 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0141 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0131 events1 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0101 events1 affected4 at risk
EG0111 events1 affected8 at risk
EG0121 events1 affected5 at risk
EG0131 events1 affected3 at risk
EG0141 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0042 events1 affected6 at risk
EG0050 events0 affected8 at risk
EG0061 events1 affected8 at risk
EG0071 events1 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0141 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0051 events1 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0062 events2 affected8 at risk
EG0072 events2 affected8 at risk
EG0081 events1 affected8 at risk
EG0093 events3 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0131 events1 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0131 events1 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0051 events1 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0131 events1 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
1 events
1 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected8 at risk
EG0080 events0 affected8 at risk
EG0092 events1 affected9 at risk
EG0101 events1 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0131 events1 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0131 events1 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
1 events
1 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
1 events
1 affected
6 at risk
EG0041 events1 affected6 at risk
EG0051 events1 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0092 events1 affected9 at risk
EG0101 events1 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0092 events2 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0102 events1 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0101 events1 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0041 events1 affected6 at risk
EG0050 events0 affected8 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0091 events1 affected9 at risk
EG0102 events1 affected4 at risk
EG0111 events1 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0142 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0122 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0041 events1 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0101 events1 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0122 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0143 events1 affected7 at risk
1 events
1 affected
6 at risk
EG0041 events1 affected6 at risk
EG0051 events1 affected8 at risk
EG0063 events3 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0092 events2 affected9 at risk
EG0103 events2 affected4 at risk
EG0111 events1 affected8 at risk
EG0122 events2 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0141 events1 affected7 at risk
2 events
2 affected
6 at risk
EG0042 events2 affected6 at risk
EG0051 events1 affected8 at risk
EG0063 events3 affected8 at risk
EG0071 events1 affected8 at risk
EG0082 events2 affected8 at risk
EG0093 events3 affected9 at risk
EG0104 events2 affected4 at risk
EG0111 events1 affected8 at risk
EG0122 events2 affected5 at risk
EG0131 events1 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0051 events1 affected8 at risk
EG0062 events2 affected8 at risk
EG0070 events0 affected8 at risk
EG0082 events2 affected8 at risk
EG0091 events1 affected9 at risk
EG0102 events1 affected4 at risk
EG0111 events1 affected8 at risk
EG0125 events2 affected5 at risk
EG0130 events0 affected3 at risk
EG0141 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0061 events1 affected8 at risk
EG0071 events1 affected8 at risk
EG0080 events0 affected8 at risk
EG0094 events3 affected9 at risk
EG0104 events2 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0093 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0122 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0112 events2 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0041 events1 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0101 events1 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0041 events1 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0122 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0041 events1 affected6 at risk
EG0050 events0 affected8 at risk
EG0062 events2 affected8 at risk
EG0070 events0 affected8 at risk
EG0082 events2 affected8 at risk
EG0091 events1 affected9 at risk
EG0105 events2 affected4 at risk
EG0111 events1 affected8 at risk
EG0124 events2 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0141 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0123 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0094 events2 affected9 at risk
EG0100 events0 affected4 at risk
EG0117 events4 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0144 events3 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0092 events1 affected9 at risk
EG0102 events1 affected4 at risk
EG0112 events2 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0142 events2 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0122 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
1 events
1 affected
6 at risk
EG0040 events0 affected6 at risk
EG0051 events1 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0082 events2 affected8 at risk
EG0092 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0142 events2 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG01111 events5 affected8 at risk
EG0122 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0141 events1 affected7 at risk
1 events
1 affected
6 at risk
EG0042 events2 affected6 at risk
EG0051 events1 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0082 events2 affected8 at risk
EG0097 events6 affected9 at risk
EG0100 events0 affected4 at risk
EG0113 events3 affected8 at risk
EG0123 events3 affected5 at risk
EG0130 events0 affected3 at risk
EG0145 events5 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0041 events1 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0131 events1 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0141 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0092 events2 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0041 events1 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0051 events1 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0122 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0121 events1 affected5 at risk
EG0131 events1 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0062 events1 affected8 at risk
EG0071 events1 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0141 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0141 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0092 events2 affected9 at risk
EG0102 events2 affected4 at risk
EG0111 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
4 events
3 affected
6 at risk
EG0040 events0 affected6 at risk
EG0051 events1 affected8 at risk
EG0062 events2 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0112 events1 affected8 at risk
EG0123 events2 affected5 at risk
EG0132 events1 affected3 at risk
EG0141 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0101 events1 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0141 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0101 events1 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0041 events1 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0141 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0101 events1 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0092 events2 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0051 events1 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0051 events1 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0051 events1 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0141 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0041 events1 affected6 at risk
EG0051 events1 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0092 events2 affected9 at risk
EG0101 events1 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0122 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
1 events
1 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0141 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
1 events
1 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0093 events2 affected9 at risk
EG0101 events1 affected4 at risk
EG0111 events1 affected8 at risk
EG0122 events2 affected5 at risk
EG0130 events0 affected3 at risk
EG0142 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0143 events2 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0126 events2 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
1 events
1 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0133 events1 affected3 at risk
EG0141 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
1 events
1 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0101 events1 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0041 events1 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0131 events1 affected3 at risk
EG0141 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0051 events1 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0051 events1 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0123 events3 affected5 at risk
EG0132 events1 affected3 at risk
EG0141 events1 affected7 at risk
2 events
1 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0122 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0041 events1 affected6 at risk
EG0050 events0 affected8 at risk
EG0061 events1 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0122 events1 affected5 at risk
EG0131 events1 affected3 at risk
EG0141 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0051 events1 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
1 events
1 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0071 events1 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0101 events1 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0112 events2 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0141 events1 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0081 events1 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
1 events
1 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0101 events1 affected4 at risk
EG0110 events0 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0041 events1 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0051 events1 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0111 events1 affected8 at risk
EG0120 events0 affected5 at risk
EG0131 events1 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0091 events1 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0 events
0 affected
6 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected8 at risk
EG0060 events0 affected8 at risk
EG0070 events0 affected8 at risk
EG0080 events0 affected8 at risk
EG0090 events0 affected9 at risk
EG0100 events0 affected4 at risk
EG0110 events0 affected8 at risk
EG0121 events1 affected5 at risk
EG0130 events0 affected3 at risk
EG0140 events0 affected7 at risk
0
OG0040
OG0050
OG0060
OG0070
OG00812.5
OG00922.2
OG0100
OG01125.0
OG01240.0
OG0130
OG01414.3
277.5536
± 10.8287
OG004552.3530± 19.5548
OG005592.2331± 26.1556
OG006593.1846± 22.2154
OG007946.0883± 19.3798
OG0081357.6103± 20.4135
ParticipantsOG0045
ParticipantsOG0057
ParticipantsOG0068
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG0004.4210± 10.1288
OG00112.8115± 27.1385
OG00224.3743± 31.2011
OG00361.4527± 33.1491
OG00492.0396± 38.4595
OG005105.5277± 25.1756
OG00697.1957± 39.3439
ParticipantsOG0044
ParticipantsOG0054
ParticipantsOG0068
ParticipantsOG0076
ParticipantsOG0087
Title
Measurements
OG000NA± NAGeoMean and GeoCV (%) were only calculated if at least 2/3 of the concentrations are quantified at the respective timepoint.
OG001NA± NAGeoMean and GeoCV (%) were only calculated if at least 2/3 of the concentrations are quantified at the respective timepoint.
OG00234.6409± 26.9986
OG00367.0799± 37.9557
OG004149.3886± 37.0769
OG005193.4242± 34.5942
OG006147.2154± 26.4979
OG007124.7274± 44.3198
OG00898.9331± 33.8567
ParticipantsOG0044
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
Title
Measurements
OG000NA± NAGeoMean and GeoCV (%) were only calculated if at least 2/3 of the concentrations are quantified at the respective timepoint.
OG001NA± NAGeoMean and GeoCV (%) were only calculated if at least 2/3 of the concentrations are quantified at the respective timepoint.
OG00242.6861± 38.1929
OG00378.2336± 35.0467
OG004166.4011± 34.1041
122.8221
± 14.8778
OG004175.0745± 34.7390
OG005471.9576± 17.1727
ParticipantsOG0043
ParticipantsOG0057
Title
Measurements
OG00019.7473± 42.6072
OG00137.4171± 14.8496
OG00283.4236± 30.8533
OG00316.8917± 33.2664
OG00432.3094± 56.2327
OG00570.7026± 50.9842
ParticipantsOG0043
ParticipantsOG0055
Title
Measurements
OG00033.0061± 35.3957
OG00161.0398± 5.0117
OG002118.0926± 29.3051
OG00325.4863± 53.6347
OG00482.7657± 47.9648
OG005141.6084± 30.8310
ParticipantsOG0042
ParticipantsOG0053
Title
Measurements
OG00038.3595± 42.1013
OG00155.0249± 39.4082
OG002135.5849± 32.8644
OG00324.7120± 83.6183
OG004NA± NAGeoMean and GeoCV (%) were only calculated if at least 2/3 of the concentrations are quantified at the respective timepoint.